CN1836694A - Medicine composition for treating cardiovascular diseases and preparation method thereof - Google Patents
Medicine composition for treating cardiovascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN1836694A CN1836694A CN 200510056760 CN200510056760A CN1836694A CN 1836694 A CN1836694 A CN 1836694A CN 200510056760 CN200510056760 CN 200510056760 CN 200510056760 A CN200510056760 A CN 200510056760A CN 1836694 A CN1836694 A CN 1836694A
- Authority
- CN
- China
- Prior art keywords
- solution
- add
- weight portion
- flos
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses one kind of cardiac vascular disease treating medicine composition and its preparation process and quality control method. The medicine composition is prepared with chrysanthemum 500-900 weight portions, honeysuckle 300-700 weight portions, haw 500-900 weight portions, sophora flower 300-700 weight portions and selfheal 300-700 weight portions. The present invention also discloses the application of the medicine composition in treating coronary heart diseases and hypertension.
Description
Invention field
The present invention relates to a kind of pharmaceutical composition and preparation method thereof, particularly relate to a kind of pharmaceutical composition for the treatment of cardiovascular disease and preparation method thereof.
Background technology
Cardiovascular disease such as hyperlipidemia, hypertension mainly betides middle-aged and elderly people, is clinical commonly encountered diseases, frequently-occurring disease, also is a class disease of serious threat human health.Lipid metabolic disorder, blood fat is too high, is arteriosclerotic main paathogenic factor; Coronary heart disease then is coronary atherosclerosis, due to coronary artery blood flow reduces, and often occur together hyperlipidemia and hypertension.This class cardiovascular diseases's sickness rate is in rising trend in China.Become commonly encountered diseases in the middle-aged and elderly people at present, frequently-occurring disease, very unhealthful, mortality rate is also high.Prevention and treatment to this class disease are one of current vital tasks.Therefore, research prevents and treats the medicine of this class disease, has huge clinical meaning and application prospect.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition for the treatment of cardiovascular disease such as hyperlipidemia, hypertension; The object of the invention also is to provide a kind of preparation of drug combination method for the treatment of cardiovascular disease such as hyperlipidemia, hypertension.
The present invention seeks to be achieved through the following technical solutions.
Pharmaceutical composition crude drug of the present invention consists of:
Flos Chrysanthemi 500-900 weight portion Flos Lonicerae 300-700 weight portion Fructus Crataegi 500-900 weight portion
Flos Sophorae 300-700 weight portion Spica Prunellae 300-700 weight portion
Pharmaceutical composition crude drug of the present invention is formed optimum ratio:
Flos Chrysanthemi 750 weight portion Flos Loniceraes 500 weight portion Fructus Crataegis 750 weight portions
Flos Sophorae 500 weight portion Spica Prunellaes 500 weight portions;
Flos Chrysanthemi 600 weight portion Flos Loniceraes 600 weight portion Fructus Crataegis 600 weight portions
Flos Sophorae 600 weight portion Spica Prunellaes 400 weight portions;
Flos Chrysanthemi 800 weight portion Flos Loniceraes 400 weight portion Fructus Crataegis 850 weight portions
Flos Sophorae 400 weight portion Spica Prunellaes 650 weight portions.
The invention described above pharmaceutical composition can be made clinical acceptable any dosage form, as medicinal tea, pill, powder, capsule, granule, drop pill, oral liquid, injection etc.
Preparation of drug combination method of the present invention is: Spica Prunellae all reaches Flos Chrysanthemi, Flos Lonicerae, Flos Sophorae half and half amount mixing, is ground into coarse powder, sieves, and gets coarse powder amount 30-50%, and is standby; The half remaining amounts of three flavors such as residue behind the coarse powder and Flos Chrysanthemi of getting add 8-12 times of water gaging and decoct 2-4 time, and each 20-60 minute, collecting decoction, filtration; Filtrate is concentrated into the clear paste that relative density is 70～80 ℃ of surveys 1.24～1.26, and is standby; Fructus Crataegi is with 5-9 times of water gaging warm macerating 1-3 time, each 0.5-2 hour, merging filtrate; Filter, filtrate is concentrated into the clear paste that relative density is 70～80 ℃ of surveys 1.24～1.26, and is standby; Get above-mentioned coarse powder and mix, add conventional adjuvant, make clinical acceptable any dosage form, as medicinal tea, pill, powder, capsule, granule, drop pill, oral liquid etc. with two kinds of clear paste.
Method for optimizing is: Spica Prunellae all reaches each 1/2 mixed powder of Flos Chrysanthemi, Flos Lonicerae, the Flos Sophorae Immaturus and is broken into coarse powder, get remaining 1/2 the adding 10 times of water gagings and decoct secondaries of three flavors such as the 43-44% residue of 14～20 order coarse powder amounts and Flos Chrysanthemi, boiled 30 minutes at every turn, filter, merging filtrate, being concentrated into relative density and being 70～80 ℃, to survey 1.24～1.26 clear paste standby; Fructus Crataegi is with suitable quantity of water 80 ℃ of warm macerating secondaries, and each 1 hour, filter, merging filtrate, being concentrated into relative density and being 70～80 ℃, to survey 1.24～1.26 clear paste standby; Get coarse powder and mix, add conventional adjuvant, make clinical acceptable any dosage form, as pill, medicinal tea, powder, capsule, granule, drop pill, oral liquid etc. with above-mentioned two kinds of concentrated solutions.
The quality determining method of pharmaceutical composition medicinal tea of the present invention comprises one or more that following discriminating is central:
A. get medicinal tea, put microscopically and observe: pollen grain similar round or circle triangle, diameter 61～97um, yellow, carving stricture of vagina fine particulate, 3 of germinal aperatures are arranged: nonglandular hair mostly is unicellular, fractures more, and wall thickness has tiny verruca; Glandular hair head turbination, 6～33 cells, diameter 27～106um, what have includes yellow substance, 2～5 cells of handle, diameter 13～57um fractures more; Calcium oxalate cluster crystal is dispersed in or sees in the parenchyma cell, diameter 9～37um, and the corner angle top is more blunt.Pollen grain spheroidal, diameter 22～38um, light yellow or closely colourless, carving stricture of vagina thorn-like, 3 of germinal aperatures.Pollen grain spheroidal, diameter 14～22um, near colourless or light yellow, the surface is more smooth, and 3 of germinal aperatures are arranged, and is bigger.The nonglandular hair many cells often have 1 or several cellular contraction, and are most imperfect, pale brown color, and there is tiny verruca on the surface.
B. get medicinal tea 5g, put in the flask, add petroleum ether (60～90 ℃) 50ml, cocurrent flow 20 minutes, filter, discard petroleum ether liquid, medicinal residues volatilize, and add dilute hydrochloric acid 5ml and ethyl acetate 100ml reflux, extract, 1 hour, filter, filtrate evaporate to dryness, residue add methanol 2ml makes dissolving, as need testing solution; Other gets the chlorogenic acid reference substance, adds ethanol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), drawing need testing solution 10ul, reference substance solution 5ul, put respectively on same silica gel H lamellae, is developing solvent with the upper solution of 7: 2.5: 2.5 butyl acetate-formic acid-water, humidity is controlled at 32%, ascending development 12～15cm takes out, and dries, put under the 365nm ultra-violet lamp and inspect, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
C. get medicinal tea 5g, put in the flask, add ethanol 50ml, refluxed 1 hour, filter, filtrate evaporate to dryness, residue add petroleum ether (30～60 ℃) and soak 2 times, each 15ml, 2 minutes; The petroleum ether liquid that inclines, residue adds ethanol 1ml makes dissolving, as need testing solution; Other gets the ursolic acid reference substance, add ethanol and make the solution that every 1ml contains 1mg, product solution is tested according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B) in contrast, draw need testing solution 10ul, reference substance solution 5ul, put respectively on same-silica gel g thin-layer plate, with 20: 5: 8: 0.5 cyclohexane extraction-chloroform-ethyl acetate-glacial acetic acid was developing solvent, launched, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and it is clear to be heated to speckle colour developing at 105 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
D. get medicinal tea 5g, put in the flask, add methanol 50ml, close plug, supersound process 30 minutes filters, filtrate evaporate to dryness, residue add water 10ml makes dissolving, is added on the polyamide column, water 100ml eluting discards water liquid, reuse ethanol 100ml eluting, collect ethanol elution, evaporate to dryness, residue add methanol 2ml makes dissolving, as need testing solution; Other gets control substance of Rutin, adds methanol and makes the solution that every 1ml contains 2mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw need testing solution 8ul, reference substance solution 3ul, putting respectively on same silica gel g thin-layer plate, is developing solvent with 8: 1: 1 ethyl acetate-formic acid-water, launches, take out, dry, spray, is put under the ultra-violet lamp (365nm) and is inspected in the test sample chromatograph than aluminum test solution with dichloro, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color.
The quality determining method of pharmaceutical composition medicinal tea of the present invention also comprises following assay:
Precision takes by weighing 120 ℃ of control substance of Rutin 20mg that are dried to constant weight, puts in the 100ml measuring bottle, and it is an amount of to add 30% methanol, and jolting makes dissolving, adds methanol and is diluted to scale, shakes up, and promptly gets the reference substance solution that every 1ml contains anhydrous rutin 0.2mg;
Precision is measured reference substance solution 1.0ml, 2.0ml, 3.0ml, 4.0ml, 5.0ml with 6.0ml, place the 25ml measuring bottle respectively, respectively add 30% methanol to 6ml, add 5% sodium nitrite solution 1ml, make mixing, placed 6 minutes, add 10% aluminum nitrate solution 1ml, shake up, placed 6 minutes, hydro-oxidation sodium test solution 10ml, add 30% methanol again to scale, shaking up, is blank with corresponding solution, according to spectrophotography (appendix VB of Chinese Pharmacopoeia version in 2000) test, the place measures trap immediately at the 500nm wavelength, with the trap is vertical coordinate, and concentration is abscissa, the drawing standard curve;
Be taken at 60 ℃ of sample 0.5g that are dried to constant weight, the accurate title, decide, and puts in the triangular flask, and the accurate methanol 100ml that adds weighs, ultrasonic 250W 50KHZ) handles 40 minutes, puts coldly, adds methanol and supplies weight, filters, precision is measured subsequent filtrate 15ml, puts in the 50ml measuring bottle, adds water and is settled to scale, shakes up; Precision is measured 3ml, puts in the 25ml measuring bottle, adds 30% methanol and is diluted to scale, shakes up as blank; Precision is measured 3ml in addition, puts in the 25ml measuring bottle, and the method under the sighting target directrix curve preparation from " adding 30% methanol to 6ml ", is measured trap in accordance with the law immediately, reads the need testing solution from standard curve; The weight that is equivalent to rutin is calculated, promptly; The every g of medicinal tea contains total flavones with rutin (C
27H
30O
16) meter, must not be less than 100mg.
Pharmaceutical composition ZHONGJUHUA of the present invention is a monarch drug; Flos Lonicerae, the Flos Sophorae Immaturus, Spica Prunellae are ministerial drug; Fructus Crataegi is the ministerial drug adjuvant drug of holding concurrently.Have effects such as calming liver and clearing heat, blood circulation promoting and blood stasis dispelling, expectorant blood fat reducing.Main component has volatile oil, flavonoid, chlorogenic acid, isochlorogenic acid, globulariacitrin, triterpenoid saponin, free ursolic acid, oleanolic acid, citric acid, Crataegolic acid, saccharide and glycoside etc.The present composition can make diseases such as headache, dizzy, insomnia alleviate, and the hyperpietic is reduced its blood pressure tangible effect is arranged; The preparation that pharmaceutical composition of the present invention is made have resist myocardial ischemia, effect such as anti-myocardial ischemia, blood fat reducing and blood pressure lowering, so effective in cure to coronary heart disease, hyperlipemia, hypertension etc.
Following experimental example and embodiment are used for explanation but are not limited to the present invention.
Experimental example 1: the rat acute cardiac muscle lacks the effect test due to the anti-isoproterenol
Choose 50 of healthy SD rats, body weight 200-260g male and female half and half.Arranging in pairs or groups at random by the body weight of animal and sex is divided into five groups, respectively as the high, medium and low three kinds of dosage groups of present composition medicinal tea (calling medicinal tea in the following text), positive drug matched group and normal saline matched group.The dosage of three kinds of dosage groups of medicinal tea rats by intraperitoneal injection medicinal tea is respectively 24g/kg, 12g/kg and 5g/kg, and (concentration is respectively 31.5 and 0.75g/ml, the administration volume is the 0.8ml/100g body weight, is respectively 40 times, 20 times and 10 times of the daily dosage of clinical adult).Be positive drug control rats lumbar injection FUFANG DANSHEN ZHUSHEYE 3.2ml/kg body weight, (0.32ml/100g is 40 times of the daily dosage of clinical adult).Saline control group (blank group) rat is intraperitoneal injection of saline 0.6ml/100g body weight then.Result of the test sees 1 and table 2.
Table 1 medicinal tea causes the influence of Acute Myocardial Ischemia in Rats electrocardiogram (ST section) to isoproterenol
| Group | Dosage (g/kg) | Number of animals (only) | Different time (branch) ST field offset value behind the injection isoproterenol (X ± SD.mV) | ||||
| 0.5 | 1 | 2 | 4 | 10 | |||
| Medicinal tea group medicinal tea group medicinal tea group Radix Salviae Miltiorrhizae Injection group normal saline group | 24 12 6 - - | 10 10 10 10 10 | 0.26**±0.68 -0.40***±0.60 -0.12***±0.30 0.30***±0.36 1.24±0.85 | 0.28**±0.71 -0.44***±0.47 -0.36***±0.27 0.27***±0.49 1.59±1.20 | 0.31***±0.71 -0.53***±0.56 0.41***±0.31 0.14***±0.35 1.66±1.07 | 0.32**±0.65 -0.29***±0.45 -0.32***±0.53 -0.32***±0.33 1.44±1.13 | 0.54*±0.4 -0.33***±0.46 0.05**±0.61 -0.41***±0.42 1.06±1.12 |
Annotate: compare with the normal saline group, learn by statistics and handle * P＞0.05, * * P＜0.05, * * * P＜0.01.
Table 2 medicinal tea causes the influence of Acute Myocardial Ischemia in Rats electrocardiogram (T ripple) to isoproterenol
| Group | Dosage (g/kg) | Number of animals (only) | The higher degree of different time (branch) T ripple behind the injection isoproterenol (X ± SD, mV) | ||||
| 0.5 | 1 | 2 | 4 | 10 | |||
| Medicinal tea group medicinal tea group medicinal tea group Radix Salviae Miltiorrhizae Injection group normal saline group | 24 12 6 - - | 10 10 10 10 10 | 0.44*±0.58 -1.08**±0.69 0.40*±0.32 0.74*±0.45 0.28±0.36 | 0.65*±0.96 -0.12**±0.75 0.57*±0.64 0.82*±0.51 1.58±0.50 | 2.32*±2.36 0.22*±0.41 1.25*±1.12 0.60*±0.39 0.64±0.74 | 2.01*±2.01 0.06*±0.57 1.08*±0.76 0.54*±0.38 0.46±0.59 | 0.54*±0.77 -0.71**±0.61 1.14*±0.57 0.21*±0.85 0.30±0.79 |
Annotate: compare * P＞0.05, * * P＜0.05 with the normal saline group.
As seen from Table 1, normal saline group rat is behind the lumbar injection isoprenaline, because heavy dose of isoproterenol can cause myocardial contraction too fast, contractility is excessive, the arteria coronaria underfilling, myocardial oxygen consumption substantially exceeds oxygen supply, myocardial ischemia occurs, the electrocardiogram that produces cardiac damage changes, and promptly ST field offset value is bigger.Under same experimental technique and condition, after three kinds of dosage of rats by intraperitoneal injection medicinal tea and the lumbar injection FUFANG DANSHEN ZHUSHEYE, significantly the infringement of the caused acute myocardial ischemia ECG ST section of antagonism isoproterenol sexually revises.Three kinds of dosages of medicinal tea refer to the infringement of Acute Myocardial Ischemia in Rats ECG ST section changes due to the anti-isoproterenol effect relatively, and the curative effect of the curative effect of middle dosage 12g/kg and low agent 6g/kg administration after than high dose 24g/kg administration is much better.This may be because during intraperitoneal injection, the high dose group drug concentrations is 3g/ml, concentration is higher, and it is higher and reduced the absorption (promptly having reduced bioavailability) of medicine to enter its osmotic pressure behind the abdominal cavity, so the high dose administration relatively poor result of curative effect on the contrary occurs.As seen from Table 2, only middle dosage (12g/kg) the administration group of medicinal tea increases Acute Myocardial Ischemia in Rats ECG T wave height due to the isoproterenol antagonism, and does not all have this effect after medicinal tea high dose (24g/kg) and low dosage (6g/kg) and the administration of FUFANG DANSHEN ZHUSHEYE high dose.In a word, from table 1 and table 2 as seen, after the medicinal tea administration (prevention administration), Acute Myocardial Ischemia in Rats due to the isoproterenol is had remarkable antagonism protective effect, and FUFANG DANSHEN ZHUSHEYE also there is this effect.
Experimental example 2: effect for reducing blood fat test
Choose 75 of healthy mices, body weight 24-26g, male and female half and half.Heavily reach sex by animal body and be divided into five groups at random, respectively as medicinal tea high and low dose group, positive drug matched group, normal saline matched group and intact animal's matched group.The mice hyperlipemia model is duplicated in the high fat diet of all ingesting of preceding four groups of mices.Medicinal tea high and low dose group mice is irritated stomach medicinal tea 12g/kg and 6g/kg (liquor strength is respectively 0.6 and 0.3g/ml, and the administration volume is the 0.4ml/20g body weight, the day for human beings clothes dosage that is equivalent to respectively to grow up 20 times and 10 times) at every turn.The positive drug control mice is irritated stomach Yunnan pollen tianqi oral liquid 0.32ml/20g body weight (be equivalent to grow up day for human beings clothes dosage 20 times) at every turn.Normal saline matched group and the normal control group mice of taking normal diet are then irritated stomach normal saline 0.4ml/20g body weight at every turn.Each treated animal gastric infusion every day 1 time, successive administration 7 days.After the last administration 24 hours, the disconnected neck of mice is put to death, collect blood and carry out serum total cholesterol and triglyceride determination.Result of the test sees Table 3.
Table 3 medicinal tea is to the influence test of hyperlipemia in mice serum lipids content
| Group | Dosage (g/kg) | Number of animals (only) | The serum lipids resultant (X ± SD, mol/L) | |
| T-CHOL | Triglyceride | |||
| Medicinal tea group medicinal tea group YUNNAN HUAFEN TIANQI YE group model group with hyperlipemia intact animal matched group | 12 6 - - - | 15 15 15 15 15 | 3.7667±1.6034** 4.1533±1.7050* 4.4667±0.1372* 5.0400±1.3092 3.9000±0.6014*** | 0.5627±0.1902* 0.4513±0.1400* 0.3860±0.1704* 0.4260±0.1773 0.4420±0.0922* |
Annotate: compare * 970.05, * * P＜0.05, * * * P＜0.01 with hyperlipemia model of a syndrome group.
As seen from Table 3, mice ingested " high fat diet " after 7 days, and total cholesterol level raises significantly in the serum.The serum total cholesterol content of model group with hyperlipemia mice illustrates that than normal control group 22.62% (P＜0.01) that on average raises mice hypercholesterolemia replication of Model is successful.The content of its serum triglycerides of " high fat diet " back is not seen obvious rising but mice ingests.Medicinal tea 12g/kg and 6g/kg can make the serum total cholesterol content of hyperlipemia in mice reduce by 25.26% (P＜0.05) and 17.59% (P＞0.05) respectively.Show that medicinal tea has the effect of remarkable reduction serum cholesterol content at 12g/kg dosage.And the Yunnan pollen tianqi oral liquid with the dosed administration of clinical dosage multiple such as medicinal tea 12g/kg (be the day for human beings clothes dosage of growing up 20 times) after, then do not see tangible cholesterol reducing effect, only than hyperlipemia model 11.38% (P＞0.05) that descends.Result of the test shows that the serum cholesterol-lowering effect of medicinal tea is better than the Yunnan pollen tianqi oral liquid.
Experimental example 3: oxygen lack resistant function test
Choose 70 of healthy male mices, body weight 1g-20g.Be divided into five groups at random by the mice body weight, respectively as the high, medium and low three kinds of dosed administration groups of medicinal tea, positive drug matched group and weight saline control group.Three kinds of dosage groups of medicinal tea mouse stomach medicinal tea 24g/kg, 12g/kg and 6g/kg (liquor strength is respectively 1.2,0.6 and 0.3g/ml, and the administration volume is the 0.4ml/20g body weight, is respectively 40 times, 20 times and 10 times of the day for human beings clothes dosage of growing up).The positive drug control group mice is irritated stomach Yunnan pollen tianqi oral liquid 0.32ml/20g body weight (be equivalent to grow up day for human beings clothes dosage 20 times).The normal saline matched group is then irritated stomach normal saline 0.4ml/20g body weight.In order to strengthen myocardial excitability, to increase myocardial oxygen consumption, after 30 minutes, give every mouse subcutaneous injection 0.1% isoproterenol hydrochloride inj 0.2ml/10g body weight in each group mouse stomach administration.Immediately every mice is put into the wide-mouth port grinding bottle that volume is 250ml separately behind the injection isoproterenol.Bottleneck is coated with vaseline and seals.Be placed with the sodica calx 5g of gauze parcel in the bottle, to absorb moisture and the carbon dioxide that mice is breathed out.Write down each mice and put into bottle, with the index of time-to-live as evaluation medicine oxygen lack resistant function to dead time-to-live time.Calculate the time-to-live of respectively organizing mice and the percentage rate (%) that calculates administration treated animal time-to-live and prolongation by following formula.Result of the test sees Table 4.
Table 4 medicinal tea is to the influence of mice normobaric hypoxia toleration
| Group | Dosage (g/kg) | Number of animals (only) | Time-to-live (X ± SD, min) | Rate elongation (%) | The P value |
| Medicinal tea group medicinal tea group medicinal tea group YUNNAN HUAFEN TIANQI YE group normal saline matched group | 24 12 6 - - | 14 14 14 14 14 | 37.57±11.09 47.19±9.43 44.04±0.61 32.36±7.99 39.07±10.29 | -3.04 20.66 14.26 -17.17 - | ＞0.05 ＜0.05 ＞0.05 ＞0.05 - |
As seen from Table 4, each organizes the isoproterenol of mouse subcutaneous injection heavy dose, can strengthen myocardial contraction dramatically, accelerates heart rate, quickens conduction, increases myocardial metabolism and oxygen consumption, causes myocardial ischemia and quickens its death.After medicinal tea 12g/kg and the 6g/kg administration, can make time-to-live of myocardial ischemia animal pattern that in various degree prolongation is arranged, than the prolongation respectively 20.66% (P＜0.05) and 14.26% (P＞0.05) of normal saline contrast.But medicinal tea there is no the effect that makes the animals survived time lengthening in 24g/kg higher dosage or Yunnan pollen tianqi oral liquid to after the mouse stomach administration.Result of the test shows, medicinal tea can the significant prolongation mice under suitable dosage under condition of normal pressure because of the dead time due to the myocardial ischemia, can recognize it has the antagonism protective effect to the myocardial ischemia mice.
Embodiment 1:
Flos Chrysanthemi 750g, Flos Lonicerae 500g, Fructus Crataegi 750g, Flos Sophorae 500g, Spica Prunellae 500g, Spica Prunellae all reach each 1/2 mixed powder of Flos Chrysanthemi, Flos Lonicerae, the Flos Sophorae Immaturus and be broken into coarse powder, get 14～20 order coarse powder 600g, and be standby; Get remaining 1/2 the adding 10 times of water gagings and decoct secondaries of three flavors such as residue (decocting a drug wrapped) behind the coarse powder and Flos Chrysanthemi, each 30 minutes, filter, merging filtrate is concentrated into 675ml, and relative density is that the clear paste of 1.24～1.26 (70～80 ℃) is standby; Fructus Crataegi is used 80 ℃ of warm macerating secondaries of suitable quantity of water, and each 1 hour, filter, merging filtrate is concentrated into 125ml, and relative density is that the clear paste of 1.24～1.26 (70～80 ℃) is standby; Get coarse powder and above-mentioned two kinds of concentrated solution mixing granulations, 80 ℃ of dryings, granulate gets medicinal tea granule 1000g (± 1%), packing, promptly.Instructions of taking: boiled water soaked after 5 minutes drinks a 5g, 3 times on the one.
Embodiment 2:
Get Flos Chrysanthemi 600g, Flos Lonicerae 600g, Fructus Crataegi 600g, Flos Sophorae 600g, Spica Prunellae 400g, Spica Prunellae all reach Flos Chrysanthemi, Flos Lonicerae, Flos Sophorae half and half amount mixing, are ground into coarse powder, sieve, and get coarse powder amount 50%, and be standby; The half remaining amounts of three flavors such as residue behind the coarse powder and Flos Chrysanthemi of getting add 8 times of water gagings and decoct 3 times, and each 40 minutes, collecting decoction filtered; Filtrate is concentrated into the clear paste that relative density is 70～80 ℃ of surveys 1.24～1.26, and is standby; Fructus Crataegi is with 5 times of water gaging warm macerating 3 times, each 0.5 hour, merging filtrate; Filter, filtrate is concentrated into the clear paste that relative density is 70～80 ℃ of surveys 1.24～1.26, and is standby; Get above-mentioned coarse powder and mix, add conventional adjuvant and make capsule with two kinds of clear paste.
Embodiment 3:
Flos Chrysanthemi 800g, Flos Lonicerae 400g, Fructus Crataegi 850g, Flos Sophorae 400g, Spica Prunellae 650g, Spica Prunellae all reach Flos Chrysanthemi, Flos Lonicerae, Flos Sophorae half and half amount mixing, are ground into coarse powder, sieve, and get coarse powder amount 30%, and be standby; The half remaining amounts of three flavors such as residue behind the coarse powder and Flos Chrysanthemi of getting add 12 times of water gagings and decoct 4 times, and each 20 minutes, collecting decoction filtered; Filtrate is concentrated into the clear paste that relative density is 70～80 ℃ of surveys 1.24～1.26, and is standby; Fructus Crataegi is with 9 times of water gaging warm macerating 1 time, 2 hours time, merging filtrate; Filter, filtrate is concentrated into the clear paste that relative density is 70～80 ℃ of surveys 1.24～1.26, and is standby; Get above-mentioned coarse powder and mix, add conventional adjuvant, make drop pill with two kinds of clear paste.
Embodiment 4: quality determining method
Carry out quality testing as the embodiment 1 preparation present composition:
A. get granule, put microscopically and observe: pollen grain similar round or circle triangle, diameter 61～97um, yellow, carving stricture of vagina fine particulate, 3 of germinal aperatures are arranged: nonglandular hair mostly is unicellular, fractures more, and wall thickness has tiny verruca; Glandular hair head turbination, 6～33 cells, diameter 27～106um, what have includes yellow substance, 2～5 cells of handle, diameter 13～57um fractures more; Calcium oxalate cluster crystal is dispersed in or sees in the parenchyma cell, diameter 9～37um, and the corner angle top is more blunt.Pollen grain spheroidal, diameter 22～38um, light yellow or closely colourless, carving stricture of vagina thorn-like, 3 of germinal aperatures.Pollen grain spheroidal, diameter 14～22um, near colourless or light yellow, the surface is more smooth, and 3 of germinal aperatures are arranged, and is bigger.The nonglandular hair many cells often have 1 or several cellular contraction, and are most imperfect, pale brown color, and there is tiny verruca on the surface.
B. get granule 5g, put in the flask, add petroleum ether (60～90 ℃) 50ml, cocurrent flow 20 minutes, filter, discard petroleum ether liquid, medicinal residues volatilize, and add dilute hydrochloric acid 5ml and ethyl acetate 100ml reflux, extract, 1 hour, filter, filtrate evaporate to dryness, residue add methanol 2ml makes dissolving, as need testing solution; Other gets the chlorogenic acid reference substance, adds ethanol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), drawing need testing solution 10ul, reference substance solution 5ul, put respectively on same silica gel H lamellae, is developing solvent with the upper solution of 7: 2.5: 2.5 butyl acetate-formic acid-water, humidity is controlled at 32%, ascending development 12～15cm takes out, and dries, put under the 365nm ultra-violet lamp and inspect, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
C. get granule 5g, put in the flask, add ethanol 50ml, refluxed 1 hour, filter, filtrate evaporate to dryness, residue add petroleum ether (30～60 ℃) and soak 2 times, each 15ml, 2 minutes; The petroleum ether liquid that inclines, residue adds ethanol 1ml makes dissolving, as need testing solution; Other gets the ursolic acid reference substance, add ethanol and make the solution that every 1ml contains 1mg, product solution is tested according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B) in contrast, draw need testing solution 10ul, reference substance solution 5ul, put respectively on same silica gel g thin-layer plate, with 20: 5: 8: 0.5 cyclohexane extraction-chloroform-ethyl acetate-glacial acetic acid is developing solvent, launches, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and it is clear to be heated to speckle colour developing at 105 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color
Embodiment 5: quality determining method
Carry out quality testing as the embodiment 1 preparation present composition:
A. get granule, put microscopically and observe: pollen grain similar round or circle triangle, diameter 61～97um, yellow, carving stricture of vagina fine particulate, 3 of germinal aperatures are arranged: nonglandular hair mostly is unicellular, fractures more, and wall thickness has tiny verruca; Glandular hair head turbination, 6～33 cells, diameter 27～106um, what have includes yellow substance, 2～5 cells of handle, diameter 13～57um fractures more; Calcium oxalate cluster crystal is dispersed in or sees in the parenchyma cell, diameter 9～37urn, and the corner angle top is more blunt.Pollen grain spheroidal, diameter 22～38um, light yellow or closely colourless, carving stricture of vagina thorn-like, 3 of germinal aperatures.Pollen grain spheroidal, diameter 14～22um, near colourless or light yellow, the surface is more smooth, and 3 of germinal aperatures are arranged, and is bigger.The nonglandular hair many cells often have 1 or several cellular contraction, and are most imperfect, pale brown color, and there is tiny verruca on the surface.
B. get granule 5g, put in the flask, add petroleum ether (60～90 ℃) 50ml, cocurrent flow 20 minutes, filter, discard petroleum ether liquid, medicinal residues volatilize, and add dilute hydrochloric acid 5ml and ethyl acetate 100 reflux, extract, 1 hour, filter, filtrate evaporate to dryness, residue add methanol 2ml makes dissolving, as need testing solution; Other gets the chlorogenic acid reference substance, adds ethanol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), drawing need testing solution 10ul, reference substance solution 5ul, put respectively on same silica gel H lamellae, is developing solvent with the upper solution of 7: 2.5: 2.5 butyl acetate-formic acid-water, humidity is controlled at 32%, ascending development 12～15cm takes out, and dries, put under the 365nm ultra-violet lamp and inspect, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
C. get granule 5g, put in the flask, add ethanol 50ml, refluxed 1 hour, filter, filtrate evaporate to dryness, residue add petroleum ether (30～60 ℃) and soak 2 times, each 15ml, 2 minutes; The petroleum ether liquid that inclines, residue adds ethanol 1ml makes dissolving, as need testing solution; Other gets the ursolic acid reference substance, add ethanol and make the solution that every 1ml contains 1mg, product solution is tested according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B) in contrast, draw need testing solution 10ul, reference substance solution 5ul, put respectively on same silica gel g thin-layer plate, with 20: 5: 8: 0.5 cyclohexane extraction-chloroform-ethyl acetate-glacial acetic acid is developing solvent, launches, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and it is clear to be heated to speckle colour developing at 105 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
D. get granule 5g, put in the flask, add methanol 50ml, close plug, supersound process 30 minutes filters, filtrate evaporate to dryness, residue add water 10ml makes dissolving, is added on the polyamide column, water 100ml eluting discards water liquid, reuse ethanol 100ml eluting, collect ethanol elution, evaporate to dryness, residue add methanol 2ml makes dissolving, as need testing solution; Other gets control substance of Rutin, adds methanol and makes the solution that every 1ml contains 2mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw need testing solution 8ul, reference substance solution 3ul, putting respectively on same silica gel g thin-layer plate, is developing solvent with 8: 1: 1 ethyl acetate-formic acid-water, launches, take out, dry, spray, is put under the ultra-violet lamp (365nm) and is inspected in the test sample chromatograph than aluminum test solution with dichloro, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
Precision takes by weighing 120 ℃ of control substance of Rutin 20mg that are dried to constant weight, puts in the 100ml measuring bottle, and it is an amount of to add 30% methanol, and jolting makes dissolving, adds methanol and is diluted to scale, shakes up, and promptly gets the reference substance solution that every 1ml contains anhydrous rutin 0.2mg;
Precision is measured reference substance solution 1.0ml, 2.0ml, 3.0ml, 4.0ml, 5.0ml with 6.0ml, place the 25ml measuring bottle respectively, respectively add 30% methanol to 6ml, add 5% sodium nitrite solution 1ml, make mixing, placed 6 minutes, add 10% aluminum nitrate solution 1ml, shake up, placed 6 minutes, hydro-oxidation sodium test solution 10ml, add 30% methanol again to scale, shaking up, is blank with corresponding solution, according to spectrophotography (appendix VB of Chinese Pharmacopoeia version in 2000) test, the place measures trap immediately at the 500nm wavelength, with the trap is vertical coordinate, and concentration is abscissa, the drawing standard curve;
Be taken at 60 ℃ of sample 0.5g that are dried to constant weight, the accurate title, decide, and puts in the triangular flask, and the accurate methanol 100ml that adds weighs, ultrasonic 250W 50KHZ) handles 40 minutes, puts coldly, adds methanol and supplies weight, filters, precision is measured subsequent filtrate 15ml, puts in the 50ml measuring bottle, adds water and is settled to scale, shakes up; Precision is measured 3ml, puts in the 25ml measuring bottle, adds 30% methanol and is diluted to scale, shakes up as blank; Precision is measured 3ml in addition, puts in the 25ml measuring bottle, and the method under the sighting target directrix curve preparation from " adding 30% methanol to 6ml ", is measured trap in accordance with the law immediately, reads the need testing solution from standard curve; The weight that is equivalent to rutin is calculated, promptly; The every g of granule contains total flavones with rutin (C
27H
30O
16) meter, must not be less than 100mg.
Claims (11)
1, a kind of pharmaceutical composition for the treatment of cardiovascular disease is characterized in that this pharmaceutical composition made by following crude drug:
Flos Chrysanthemi 500-900 weight portion Flos Lonicerae 300-700 weight portion Fructus Crataegi 500-900 weight portion
Flos Sophorae 300-700 weight portion Spica Prunellae 300-700 weight portion.
2, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition made by following crude drug:
Flos Chrysanthemi 750 weight portion Flos Loniceraes 500 weight portion Fructus Crataegis 750 weight portions
Flos Sophorae 500 weight portion Spica Prunellaes 500 weight portions.
3, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition made by following crude drug:
Flos Chrysanthemi 600 weight portion Flos Loniceraes 600 weight portion Fructus Crataegis 600 weight portions
Flos Sophorae 600 weight portion Spica Prunellaes 400 weight portions.
4, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition made by following crude drug: Flos Chrysanthemi 800 weight portion Flos Loniceraes 400 weight portion Fructus Crataegis 850 weight portion Flos Sophoraes 400 weight portion Spica Prunellaes 650 weight portions.
5, as claim 1,2,3 or 4 described preparation of drug combination methods, it is characterized in that this method is:
Spica Prunellae all reaches Flos Chrysanthemi, Flos Lonicerae, Flos Sophorae half and half amount mixing, is ground into coarse powder, sieves, and gets coarse powder amount 30-50%, and is standby; The half remaining amounts of three flavors such as residue behind the coarse powder and Flos Chrysanthemi of getting add 8-12 times of water gaging and decoct 2-4 time, and each 20-60 minute, collecting decoction, filtration; Filtrate is concentrated into the clear paste that relative density is 70～80 ℃ of surveys 1.24～1.26, and is standby; Fructus Crataegi is with 5-9 times of water gaging warm macerating 1--3 time, each 0.5-2 hour, merging filtrate; Filter, filtrate is concentrated into the clear paste that relative density is 70～80 ℃ of surveys 1.24～1.26, and is standby; Get above-mentioned coarse powder and mix, add conventional adjuvant, make medicinal tea, pill, powder, capsule, granule, drop pill or oral liquid with two kinds of clear paste.
6, preparation of drug combination method as claimed in claim 5 is characterized in that this method is:
Spica Prunellae all reaches each 1/2 mixed powder of Flos Chrysanthemi, Flos Lonicerae, the Flos Sophorae Immaturus and is broken into coarse powder, get remaining 1/2 the adding 10 times of water gagings and decoct secondaries of three flavors such as the 43-44% residue of 14～20 order coarse powder amounts and Flos Chrysanthemi, each 30 minutes, filter, merging filtrate, being concentrated into relative density and being 70～80 ℃, to survey 1.24～1.26 clear paste standby; Fructus Crataegi is with suitable quantity of water 80 ℃ of warm macerating secondaries, and each 1 hour, filter, merging filtrate, being concentrated into relative density and being 70～80 ℃, to survey 1.24～1.26 clear paste standby; Get coarse powder and mix, add conventional adjuvant, make medicinal tea, pill, powder, capsule, granule, drop pill or oral liquid with above-mentioned two kinds of concentrated solutions.
7, as the quality determining method of the oral liquid of claim 1,2,3 or 4 described pharmaceutical compositions, it is characterized in that this method comprises one or more in the following discriminating:
A. get medicinal tea, put microscopically and observe: pollen grain similar round or circle triangle, diameter 61～97um, yellow, carving stricture of vagina fine particulate, 3 of germinal aperatures are arranged: nonglandular hair mostly is unicellular, fractures more, and wall thickness has tiny verruca; Glandular hair head turbination, 6～33 cells, diameter 27～106um, what have includes yellow substance, 2～5 cells of handle, diameter 13～57um fractures more; Calcium oxalate cluster crystal is dispersed in or sees in the parenchyma cell, diameter 9～37um, and the corner angle top is more blunt; Pollen grain spheroidal, diameter 22～38um, light yellow or closely colourless, carving stricture of vagina thorn-like, 3 of germinal aperatures; Pollen grain spheroidal, diameter 14～22um, near colourless or light yellow, the surface is more smooth, and 3 of germinal aperatures are arranged, and is bigger; The nonglandular hair many cells often have 1 or several cellular contraction, and are most imperfect, pale brown color, and there is tiny verruca on the surface;
B. get medicinal tea 5g, put in the flask, add 60～90 ℃ petroleum ether 50ml, refluxed 20 minutes, filter, discard petroleum ether liquid, medicinal residues volatilize, and add dilute hydrochloric acid 5ml and ethyl acetate 100ml reflux, extract, 1 hour, filter, filtrate evaporate to dryness, residue add methanol 2ml makes dissolving, as need testing solution; Other gets the chlorogenic acid reference substance, adds ethanol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography, drawing need testing solution 10ul, reference substance solution 5ul, put respectively on same silica gel H lamellae, is developing solvent with the upper solution of 7: 2.5: 2.5 butyl acetate-formic acid-water, humidity is controlled at 32%, ascending development 12～15cm takes out, and dries, put under the 365nm ultra-violet lamp and inspect, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
C. get medicinal tea 5g, put in the flask, add ethanol 50ml, refluxed 1 hour, filter, filtrate evaporate to dryness, residue add 30～60 ℃ of petroleum ether and soak 2 times, each 15ml, 2 minutes; The petroleum ether liquid that inclines, residue adds ethanol 1ml makes dissolving, as need testing solution; Other gets the ursolic acid reference substance, add ethanol and make the solution that every 1ml contains 1mg, product solution is tested according to thin layer chromatography in contrast, draw need testing solution 10ul, reference substance solution 5ul, put respectively on same silica gel g thin-layer plate, with 20: 5: 8: 0.5 cyclohexane extraction-chloroform-ethyl acetate-glacial acetic acid is developing solvent, launches, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and it is clear to be heated to speckle colour developing at 105 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
D. get medicinal tea 5g, put in the flask, add methanol 50ml, close plug, supersound process 30 minutes filters, filtrate evaporate to dryness, residue add water 10ml makes dissolving, is added on the polyamide column, water 100ml eluting discards water liquid, reuse ethanol 100ml eluting, collect ethanol elution, evaporate to dryness, residue add methanol 2ml makes dissolving, as need testing solution; Other gets control substance of Rutin, adds methanol and makes the solution that every 1ml contains 2mg, in contrast product solution; Test according to thin layer chromatography, draw need testing solution 8ul, reference substance solution 3ul, putting respectively on same silica gel g thin-layer plate, is developing solvent with 8: 1: 1 ethyl acetate-formic acid-water, launches, take out, dry, spray, is put under the outer light modulation of purple 365nm and is inspected in the test sample chromatograph than aluminum test solution with dichloro, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color.
8, the quality determining method of the medicinal tea of pharmaceutical composition as claimed in claim 7 is characterized in that this method also comprises following assay:
Precision takes by weighing 120 ℃ of control substance of Rutin 20mg that are dried to constant weight, puts in the 100ml measuring bottle, and it is an amount of to add 30% methanol, and jolting makes dissolving, adds methanol and is diluted to scale, shakes up, and promptly gets the reference substance solution that every 1ml contains anhydrous rutin 0.2mg;
Precision is measured reference substance solution 1.0ml, 2.0ml, 3.0ml, 4.0ml, 5.0ml and 6.0ml, place the 25ml measuring bottle respectively, respectively add 30% methanol to 6ml, add 5% sodium nitrite solution 1ml, make mixing, placed 6 minutes, add 10% aluminum nitrate solution 1ml, shake up, placed 6 minutes, hydro-oxidation sodium test solution 10ml, add 30% methanol again to scale, shaking up, is blank with corresponding solution, according to the spectrophotography test, the place measures trap immediately at the 500nm wavelength, with the trap is vertical coordinate, and concentration is abscissa, the drawing standard curve;
Be taken at 60 ℃ of sample 0.5g that are dried to constant weight, the accurate title, decide, and puts in the triangular flask, and the accurate methanol 100ml that adds weighs, 250W, 50KHZ supersound process 40 minutes is put coldly, adds methanol and supplies weight, filters, precision is measured subsequent filtrate 15ml, puts in the 50ml measuring bottle, adds water and is settled to scale, shakes up; Precision is measured 3ml, puts in the 25ml measuring bottle, adds 30% methanol and is diluted to scale, shakes up as blank; Precision is measured 3ml in addition, puts in the 25ml measuring bottle, and the method under the sighting target directrix curve preparation from " adding 30% methanol to 6ml ", is measured trap in accordance with the law immediately, reads the need testing solution from standard curve; The weight that is equivalent to rutin is calculated, promptly; The every g of medicinal tea contains total flavones with rutin (C
27H
30O
16) meter, must not be less than 100mg.
9, as claim 1,2, the application of 3 or 4 described pharmaceutical compositions in the medicine of preparation treatment coronary heart disease or hypertension.
10, pharmaceutical composition as claimed in claim 9 is meant in preparation treatment coronary heart disease and resists myocardial ischemia.
11, pharmaceutical composition as claimed in claim 9 is meant anti-myocardial ischemia in preparation treatment coronary heart disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100567605A CN100391491C (en) | 2005-03-25 | 2005-03-25 | Medicine composition for treating cardiovascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100567605A CN100391491C (en) | 2005-03-25 | 2005-03-25 | Medicine composition for treating cardiovascular diseases and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1836694A true CN1836694A (en) | 2006-09-27 |
| CN100391491C CN100391491C (en) | 2008-06-04 |
Family
ID=37014288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100567605A Active CN100391491C (en) | 2005-03-25 | 2005-03-25 | Medicine composition for treating cardiovascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100391491C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104887844A (en) * | 2015-05-28 | 2015-09-09 | 兰毅 | Medicinal composition for resisting atherosclerosis and application thereof |
| CN109580846A (en) * | 2019-01-22 | 2019-04-05 | 北京九龙制药有限公司 | A kind of quality determining method of compound Chinese medicinal preparation that treating hyperuricemia |
| CN110772484A (en) * | 2019-11-12 | 2020-02-11 | 安徽协和成制药有限公司 | Fried sophora flower formula particle and preparation method and quality standard detection method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1183943C (en) * | 2002-12-03 | 2005-01-12 | 郭志忠 | Tea, medicated tea and buccal tablet for lowering blood pressure and reducing blood fat and their prepn process |
-
2005
- 2005-03-25 CN CNB2005100567605A patent/CN100391491C/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104887844A (en) * | 2015-05-28 | 2015-09-09 | 兰毅 | Medicinal composition for resisting atherosclerosis and application thereof |
| CN109580846A (en) * | 2019-01-22 | 2019-04-05 | 北京九龙制药有限公司 | A kind of quality determining method of compound Chinese medicinal preparation that treating hyperuricemia |
| CN110772484A (en) * | 2019-11-12 | 2020-02-11 | 安徽协和成制药有限公司 | Fried sophora flower formula particle and preparation method and quality standard detection method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100391491C (en) | 2008-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1806846A (en) | Chinese medicinal composition, its preparation process and quality control method | |
| CN100345558C (en) | Extract product of general flavone of kudzuvine root, preparation method and application | |
| CN104224811A (en) | Salvia miltiorrhiza medicine and preparation method thereof | |
| CN1762465A (en) | Rhinitis gel, its preparation method and quality control technology | |
| CN1706397A (en) | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte | |
| CN100391491C (en) | Medicine composition for treating cardiovascular diseases and preparation method thereof | |
| CN101040906A (en) | Injection for treating cardiovascular or cerebrovascular disease and the preparing method and the quality control method | |
| CN1733054A (en) | Dogwood fruit extract and its preparation process | |
| CN1299702C (en) | Preparation of medicine preparation of orthopedics department and its use | |
| CN1887324A (en) | Chinese composition and its prepn process and quality control method | |
| CN102976943A (en) | Alpha-crystal form substance of danshinolic acid A, preparation method, pharmaceutical composition and application | |
| CN1823982A (en) | Chinese medicinal preparation for liver soothing and speen fortifying and its manufacturing method | |
| CN1973853A (en) | Hemostatic and analgetic medicine composition and its prepn process | |
| CN1872280A (en) | Composition of Chinese traditional medicine for treating allergic rhinitis, and preparation method | |
| CN1739650A (en) | Cappillary artemisia-cape jasmine-rhubarb soft capsule and its prepn process | |
| CN1274711C (en) | Method of preparing general phenolic acid of red sange root for treating hepatic fibrosis | |
| CN1732964A (en) | Pharmaceutical composition, its preparation process and usage | |
| CN101077364A (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN1176690C (en) | Medicine for treating chronic nephritis | |
| CN1416880A (en) | New use of powder for regulating liver and spleen and its active part | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| CN1176677C (en) | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1704072A (en) | Heat clearing Chinese proprietary capsule(tablet) of 'Ganlu Xiaodu' for treating cold and its preparation process | |
| CN1557415A (en) | Medicine preparation for treating liver and gallbladder disease and its preparing process | |
| CN1278698C (en) | Freeze dried injection of seeding of autumnal sowthistle-leaf ixeris and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190123 Address after: 408099 1 Tai Chi Road, Fuling District, Chongqing Patentee after: Chongqing Taiji Industry (Group) Co., Ltd. Address before: 400015 28th Floor of Tai Tai Tai Building, No. 1 Chongqing Village, Two Crossings of Yuzhong District, Chongqing Patentee before: Chongqing Dayi Technology Investment Co., Ltd. |
|
| TR01 | Transfer of patent right |